Skin Conditions — Acne, Eczema, and Psoriasis Explained: Causes, Treatments, and What Actually Works
Skin conditions are among the most common health problems in the world, yet they are also among the most misunderstood and undertreated. Acne, eczema, and psoriasis together affect hundreds of millions of people globally and can cause significant physical discomfort, scarring, and psychological distress. This guide explains each condition clearly — what it is, what causes it, how it is treated, and what the latest medical evidence says about managing it well.
Skin disorders are the fourth most common cause of non-fatal disease burden globally, affecting one in four Americans. A dermatologist can accurately diagnose and tailor treatment for each condition. Source: American Academy of Dermatology
Skin Conditions by the Numbers
The scale of skin disease worldwide is far larger than most people realise, and the burden — physical, psychological, and economic — is substantial.
A Quick Guide: How to Tell These Three Conditions Apart
Before going into each condition in detail, it helps to understand the key differences. All three cause skin inflammation, but they look different, appear in different locations, and have different underlying causes and triggers.
| Feature | Acne | Eczema (Atopic Dermatitis) | Psoriasis |
|---|---|---|---|
| Appearance | Pimples, blackheads, whiteheads, cysts | Dry, red, intensely itchy patches; may weep or crust | Thick, silvery-scaled plaques on red skin; well-defined edges |
| Most common location | Face, back, chest, shoulders | Elbow creases, behind knees, neck, face (in children) | Elbows, knees, scalp, lower back |
| Main cause | Blocked pores, bacteria, hormones, excess oil | Immune overreaction, skin barrier defect, triggers | Immune-driven skin cell overproduction (autoimmune) |
| Itching | Rarely | Severe — the defining symptom | Moderate to severe in many patients |
| Age group | Primarily teens and young adults; can persist or begin in adulthood | Often begins in infancy; can persist to adulthood | Typically first appears in adults aged 20 to 60 |
| Is it contagious? | No | No | No |
Acne — The World's Most Common Skin Condition
Acne vulgaris is a chronic inflammatory condition of the hair follicles and sebaceous (oil) glands. It affects up to 85 percent of people between the ages of 12 and 24 at some point, and a growing number of adults — particularly women — experience acne well into their 30s and 40s. Despite its prevalence, acne is frequently dismissed as a cosmetic concern, when in reality it can cause lasting physical scarring and significant psychological harm including anxiety, depression, and lowered self-esteem.
The underlying process involves four interacting factors: excess sebum (oil) production driven by androgens, the clogging of hair follicles with dead skin cells, colonisation by the bacterium Cutibacterium acnes, and a resulting immune inflammatory response. Hormonal fluctuations — during puberty, the menstrual cycle, pregnancy, or conditions like polycystic ovary syndrome (PCOS) — are among the most powerful triggers. Diet may also play a role: strong evidence links high glycaemic index foods and dairy to increased acne severity in genetically susceptible individuals, though individual responses vary considerably.
Acne Severity Scale
Dermatologists grade acne as mild (mainly blackheads and whiteheads with few pimples), moderate (more widespread pimples, some deeper lesions), or severe (multiple deep, inflamed nodules and cysts that carry a high risk of permanent scarring). Severe acne should always be treated by a dermatologist, as over-the-counter products alone are insufficient and delay to treatment increases scarring risk.
Treating Acne — What the Evidence Says
Treatment depends on severity, but the most important principle across all guidelines is this: acne is best treated with a combination approach targeting multiple causes simultaneously. Monotherapy (one treatment alone) is consistently less effective than combinations.
| Treatment | Type | Best For | Key Notes |
|---|---|---|---|
| Benzoyl Peroxide | OTC Topical | Mild to moderate acne | Kills C. acnes bacteria; reduces inflammation; available in 2.5% to 10% concentrations. Start low to minimise dryness. The AAD recommends it as first-line OTC treatment. |
| Salicylic Acid | OTC Topical | Blackheads, whiteheads, mild acne | Unclogs pores by dissolving dead skin cells; best for comedonal (non-inflammatory) acne rather than deep pimples |
| Topical Retinoids (tretinoin, adapalene) | First Line Rx | All acne types | The AAD recommends topical retinoids as a cornerstone of acne treatment. Accelerate skin cell turnover, prevent clogged pores, and reduce inflammation. Adapalene 0.1% now available OTC. Causes initial dryness; results take 8 to 12 weeks. |
| Topical Antibiotics (clindamycin, erythromycin) | First Line Rx | Moderate inflammatory acne | Always used in combination with benzoyl peroxide to prevent antibiotic resistance. Never used alone as monotherapy per current AAD guidelines. |
| Oral Antibiotics (doxycycline, minocycline) | Second Line Rx | Moderate to severe acne | Effective but limited to short courses (3 to 6 months maximum) due to resistance risk. Always combined with a topical retinoid. |
| Combined Oral Contraceptives | First Line (women) | Hormonal acne in women | FDA-approved for acne treatment. Reduce androgen-driven sebum production. Effective when hormonal fluctuations are a clear trigger. |
| Isotretinoin (Accutane/Roaccutane) | Severe / Scarring | Severe, nodular, or scarring acne | The most effective acne treatment available; achieves long-term remission in ~85% of patients. Requires strict monitoring due to teratogenicity and other risks. Prescribed by dermatologists only. |
Most acne cases respond well to the right combination of topical treatments. Severe or scarring acne requires prescription medication and should be managed by a dermatologist. Source: American Academy of Dermatology
Eczema (Atopic Dermatitis) — The Itch That Rashes
Atopic dermatitis — commonly called eczema — is a chronic inflammatory skin condition characterised by intensely itchy, dry, red, and inflamed skin. It affects approximately 223 million people worldwide and is the most burdensome skin disease measured by disability-adjusted life years in the Global Burden of Disease study. Unlike acne, eczema often begins in infancy or early childhood, though it can first appear at any age and, in many cases, persists for life.
The condition involves two interacting problems: a defective skin barrier and an overactive immune response. The skin barrier in eczema patients — often linked to mutations in the gene encoding the protein filaggrin — is abnormally permeable, allowing moisture to escape and environmental allergens to penetrate. This triggers a Th2-dominant immune response that drives the inflammation, dryness, and itch characteristic of the condition. The intense itch, in turn, leads to scratching, which damages the barrier further and creates a destructive itch-scratch cycle.
Common triggers include soap and detergents, wool fabrics, heat and sweat, dust mites, pet dander, certain foods (particularly in young children), stress, and changes in temperature or humidity. Identifying and avoiding personal triggers, alongside consistent skincare and medical treatment, is the cornerstone of eczema management.
The Atopic March
Eczema is often the first condition in a sequence called the atopic march. Infants with atopic dermatitis have a significantly elevated risk of developing food allergies, then allergic rhinitis (hay fever), and then asthma as they grow. This is because the leaky skin barrier allows allergen sensitisation from an early age. Early, effective treatment of eczema may help interrupt this progression, which is one reason dermatologists recommend starting treatment promptly rather than waiting.
Treating Eczema — From Moisturisers to Biologics
The treatment of eczema is stepwise: daily moisturising forms the foundation, then topical anti-inflammatory treatments for flares, then systemic options for those with moderate to severe disease that does not respond adequately to topicals. A major advance in recent years has been the approval of biologic drugs that target the specific immune pathways driving eczema, with response rates far higher than older systemic treatments.
| Treatment | Type | Stage | Key Notes |
|---|---|---|---|
| Daily Emollients (Moisturisers) | Foundation | All severity levels | The single most important eczema management step. Applied twice daily or more to intact and affected skin. Restores the skin barrier. Thick creams and ointments are more effective than lotions. Should be applied within 3 minutes of bathing. |
| Topical Corticosteroids | First Line | Active flares — mild to moderate | The most widely used eczema treatment. Applied during flares; strength matched to body area (lower potency for face and skin folds). Not for long-term daily use on the same area. |
| Topical Calcineurin Inhibitors (tacrolimus, pimecrolimus) | First Line | Face, skin folds, sensitive areas | Steroid-free anti-inflammatory option; ideal for areas where steroids carry more risk. Particularly useful for long-term maintenance on the face. |
| Dupilumab (Dupixent) | Biologic — IL-4/13 | Moderate to severe | A landmark treatment targeting the IL-4 and IL-13 immune pathways central to eczema. Clinical trials show 50 to 60% of patients achieve clear or near-clear skin. Approved for adults, adolescents, and children aged 6 months and above. |
| Tralokinumab, Lebrikizumab | Biologic — IL-13 | Moderate to severe | Newer IL-13-specific biologics approved in Europe and the U.S. for adults with moderate to severe eczema. Comparable efficacy to dupilumab in head-to-head studies. |
| JAK Inhibitors (upadacitinib, abrocitinib) | Oral — targeted | Moderate to severe | Oral once-daily pills that inhibit JAK signalling pathways. Fast-acting with high efficacy. Require monitoring for blood counts and lipids; not for all patients due to safety profile. |
Psoriasis — More Than a Skin Condition
Psoriasis is a chronic, immune-mediated inflammatory disease that causes the skin to go through its normal cell turnover cycle in 3 to 5 days instead of the usual 28 to 30 days. The result is a rapid build-up of skin cells that form thick, silvery-scaled plaques on the surface — most commonly on the elbows, knees, scalp, and lower back. It affects roughly 125 million people worldwide, representing 2 to 3 percent of the global population, and is associated with a significantly increased risk of psoriatic arthritis, cardiovascular disease, metabolic syndrome, depression, and inflammatory bowel disease.
Psoriasis is not just a skin condition — it is now firmly established as a systemic inflammatory disease. The same immune dysregulation that drives plaques on the skin creates low-grade inflammation throughout the body, which is why cardiovascular risk in moderate to severe psoriasis is comparable to that of type 2 diabetes. This makes effective treatment about far more than appearance. The American Academy of Dermatology guidelines emphasise that all patients with psoriasis should be screened for cardiovascular risk factors, metabolic syndrome, and depression.
Psoriatic Arthritis — Know the Signs
Up to 30 percent of people with psoriasis develop psoriatic arthritis, a painful inflammatory joint condition. It can cause joint swelling, stiffness (especially in the morning), pain in tendons and where tendons attach to bone, and swelling of entire fingers or toes (dactylitis). Psoriatic arthritis can develop before, during, or after skin symptoms appear. Early diagnosis and treatment significantly reduces the risk of permanent joint damage, so anyone with psoriasis who develops joint symptoms should see a rheumatologist promptly.
Treating Psoriasis — From Topicals to Transformative Biologics
Psoriasis treatment has been transformed over the past decade by the development of biologic therapies. These precision medications target the specific cytokines (immune proteins) that drive psoriasis, producing clear or near-clear skin in 70 to 90 percent of patients with moderate to severe disease — outcomes that were unimaginable with older systemic treatments. For mild psoriasis, topical treatments remain the foundation.
| Treatment | Type | Severity | Key Notes |
|---|---|---|---|
| Topical Corticosteroids | First Line Topical | Mild to moderate | Most commonly prescribed psoriasis treatment; reduce inflammation and slow cell turnover; used in combination with vitamin D analogues for improved efficacy |
| Vitamin D Analogues (calcipotriol) | First Line Topical | Mild to moderate | Slows skin cell overproduction; frequently combined with a topical steroid in a fixed-dose formulation (Enstilar, Dovobet) for superior results and convenience |
| Phototherapy (UVB / PUVA) | Second Line | Moderate — widespread | Narrowband UVB light therapy is highly effective for widespread psoriasis; 70 to 80% of patients improve significantly. Administered in a dermatology clinic 2 to 3 times per week. AAD-endorsed first-line option for moderate disease. |
| Methotrexate | Traditional Systemic | Moderate to severe | An immunosuppressant used for decades; effective and affordable; requires regular blood monitoring for liver and bone marrow effects; not suitable during pregnancy |
| IL-17 Inhibitors (secukinumab, ixekizumab) | Biologic | Moderate to severe | Among the most effective psoriasis treatments available; 70 to 80% of patients achieve PASI 90 (90% skin clearance) in clinical trials. Also effective for psoriatic arthritis. |
| IL-23 Inhibitors (guselkumab, risankizumab) | Biologic | Moderate to severe | The newest class with the highest clearance rates — some trials show PASI 100 (complete clearance) in over 50% of patients. Quarterly or 6-monthly dosing after initial phase improves convenience significantly. |
| TNF Inhibitors (adalimumab, etanercept) | Biologic | Moderate to severe | Older biologics with good long-term safety data; effective for both skin and joint disease; biosimilar versions now available, reducing cost significantly |
Psoriasis plaques are characterised by well-defined red patches covered with thick, silvery scales. Modern biologic treatments can achieve complete or near-complete clearance in the majority of patients with moderate to severe disease. Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Lifestyle Factors That Affect All Three Conditions
While each condition has its own specific treatments, certain lifestyle factors meaningfully influence all three. Stress is a well-documented trigger for flares in eczema and psoriasis, and contributes to hormonal changes that worsen acne. The mechanism is direct: psychological stress activates the hypothalamic-pituitary-adrenal axis, driving cortisol and androgen release that increase sebum production in acne, and activates mast cells and neuropeptides in the skin that trigger eczema and psoriasis flares.
Sleep is when the skin repairs itself most actively. Chronic poor sleep is associated with increased inflammatory cytokines that worsen all inflammatory skin conditions and impairs the skin barrier repair that is critical in eczema. Diet has varying levels of evidence across the three conditions. The strongest dietary evidence is for acne (high glycaemic foods and dairy worsening severity) and for psoriasis (where obesity, alcohol, and a pro-inflammatory diet worsen disease and reduce biologic response rates). For eczema, eliminating specific trigger foods — when they are a confirmed individual trigger — can reduce flare frequency, but broad elimination diets without confirmed allergies are not recommended.
When to See a Dermatologist
Over-the-counter products are a reasonable starting point for mild symptoms, but certain situations require a professional diagnosis and prescription treatment. See a dermatologist if:
- Your acne is moderate to severe, involves deep painful cysts, or is leaving scars — this needs prescription treatment without delay
- Your eczema is not adequately controlled with regular moisturising and a short course of mild steroid cream, or is severely affecting your sleep and quality of life
- You have psoriasis covering a significant body surface area, or it is affecting your face, hands, feet, nails, or joints
- Any skin condition is causing significant psychological distress, depression, or social withdrawal — this is medically important and affects treatment decisions
- You have not received a definitive diagnosis and are self-treating based on an assumption about which condition you have
- A skin condition appears suddenly in a new pattern, or is accompanied by joint pain, fever, or systemic symptoms
- You have tried multiple OTC products for several weeks without meaningful improvement
Key Takeaways
- Acne, eczema, and psoriasis are among the world's most common diseases — together affecting hundreds of millions of people — and all three are highly treatable with the right approach
- Acne is best treated with combination therapy targeting bacteria, oil production, and cell turnover simultaneously; topical retinoids are the cornerstone of treatment
- Eczema management begins with daily emollient use; biologic drugs like dupilumab now offer near-complete clearance for moderate to severe cases that do not respond to topicals
- Psoriasis is a systemic inflammatory disease, not just a skin condition; patients have elevated cardiovascular and metabolic risk that needs monitoring and management
- IL-23 and IL-17 inhibitor biologics have transformed psoriasis treatment, achieving complete skin clearance in more than half of patients with moderate to severe disease
- Stress, poor sleep, smoking, and alcohol worsen all three conditions and should be addressed as part of any management plan
- Moderate to severe disease, scarring, joint involvement, or significant psychological impact are all reasons to seek dermatology care promptly rather than self-treating
More Health Guides, Written Clearly
Browse our full library of medically reviewed articles on skin health, pain relief, immune health, sleep, and more.
Explore All Health ArticlesSources and References
- American Academy of Dermatology — Skin Conditions by the Numbers — AAD Statistics
- International Eczema Council / GBD 2022 — Global Report on Atopic Dermatitis 2022
- PMC / NCBI — Advancements in Understanding and Treating Psoriasis: Pathophysiology and Therapeutic Approaches — 2025
- AAD — Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis
- Trilliant Health — Increase in Skin Conditions and Evolving Treatment Patterns — 2024
- PMC / NCBI — Atopic Dermatitis: A Review of Diagnosis and Treatment — 2024
- Springer — Biologics in the Treatment of Atopic Dermatitis: Approved Substances and Advanced Trials — 2025
- Dermatology Times — Psoriasis Therapies in 2024 and Beyond
- Mayo Clinic — Psoriasis: Diagnosis and Treatment
- NIAMS / NIH — Psoriasis Overview — National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Harvard Health Publishing — Skin Health and Dermatology — Harvard Medical School